Skip to search formSkip to main contentSkip to account menu

LBH589

Known as: (2E)-N-hydroxy-3-(4-(((2-(2-methyl-1h-indol-3-yl)ethyl)amino)methyl)phenyl)prop-2-enamide, LBH 589, NVP-LBH589 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

panobinostat

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Preclinical activity of LBH 589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia
Histone deacetylases (HDACs) have been identified as therapeutic targets due to their regulatory function in chromatin structure… 
2012
2012
The HDAC inhibitor LBH 589 enhances the anti-myeloma effects of the IGF-1 RTK inhibitor picropodophyllin
Miguel Lemaire*, Charlotte Fristedt*, Prasoon Agarwal, Eline Menu, Els Van Valckenborgh, Elke De Bryune, Anders Österborg, Peter… 
2010
2010
A phase I study of panobinostat (LBH589) with capecitabine with or without lapatinib.
1115 Background: In vivo experiments have demonstrated synergy when the histone deacetylase (HDAC) inhibitors are combined with… 
2010
2010
Interim results for the phase II study of panobinostat (LBH589) in patients (Pts) with relapsed/refractory Hodgkin's lymphoma (HL) after autologous hematopoietic stem cell transplant (AHSCT).
8007 Background: Panobinostat (PAN) is a pan-deacetylase inhibitor targeting epigenetic and non-epigenetic oncogenic pathways. In… 
2010
2010
PANORAMA 2: A phase II study of panobinostat (LBH589) in combination with bortezomib (BTZ) and dexamethasone (DEX) in patients with relapsed and BTZ-refractory multiple myeloma (MM).
TPS308 Background: BTZ, a backbone of novel therapy for patients (pts) with MM, is an effective agent but pts will relapse and… 
2010
2010
A phase II trial of oral panobinostat (LBH589), a novel deacetylase inhibitor (DACi) in patients with primary myelofibrosis (PMF), post-essential thrombocythemia (ET) myelofibrosis, and post…
TPS283 Background: Medical treatment options for myelofibrosis (MF) are palliative in nature. Short of allogeneic stem cell… 
2010
2010
Phase I study of LBH589 in combination with erlotinib for advanced aerodigestive tract cancers.
e13016 Background: It has previously been demonstrated that the addition of LBH589 (L) to erlotinib (E) can enhance the… 
2009
2009
Panobinostat (LBH589): a novel pan-deacetylase inhibitor with activity in T cell lymphoma
Panobinostat is a novel cinnamic hydroxamic acid pan-deacetylase inhibitor able to induce hyperacetylation of lysine residues on… 
2007
2007
Anti-leukemia activity of histone deacetylase (HDAC) inhibitor LBH589 involves depletion of EZH2 and DNA methyltransferase (DNMT) 1 through disruption of their chaperone association with heat shock…
10501 Background: LBH589 is a hydroxamate pan-HDAC inhibitor (HA-HDI) that also inhibits HDAC6, which induces acetylation of… 
2004
2004
A combination of histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC and AML cells with constitutively active mutant FLT-3 tyrosine kinase.
6541 Background: We have reported that treatment with histone deacetylase inhibitors, LAQ824 and LBH589 (Novartis Pharma AG), and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)